Myriad Genetics Inc (MYGN)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 69.89% | 69.15% | 69.06% | 68.79% | 68.64% | 68.89% | 68.34% | 69.31% | 70.22% | 70.68% | 71.55% | 71.38% | 71.39% | 70.94% | 70.51% | 68.50% | 68.03% | 69.77% | 70.86% | 73.71% |
| Operating profit margin | -12.14% | -14.06% | -19.43% | -30.11% | -34.17% | -37.04% | -36.76% | -23.18% | -18.23% | -18.26% | -23.16% | -23.26% | -27.58% | -28.58% | -23.45% | -35.82% | -52.03% | -41.91% | -36.28% | -22.21% |
| Pretax margin | -14.73% | -14.16% | -19.52% | -30.42% | -34.81% | -38.40% | -37.92% | -24.01% | -20.73% | -19.96% | -7.14% | -4.97% | -8.27% | -10.13% | -23.07% | -36.65% | -51.89% | -40.95% | -34.97% | -22.67% |
| Net profit margin | -15.20% | -14.08% | -19.35% | -30.30% | -34.96% | -37.36% | -35.51% | -21.05% | -16.51% | -11.69% | -2.62% | -1.20% | -3.94% | -9.32% | -15.64% | -27.26% | -41.29% | -32.49% | -31.24% | -19.49% |
Myriad Genetics Inc has shown a steady decrease in its gross profit margin from around 73% in March 2020 to approximately 69% by December 2024. This indicates a declining trend in the company's ability to generate profits from its core operations.
The operating profit margin of Myriad Genetics Inc reflects a significant loss-making situation, with negative margins ranging from -22% in March 2020 to around -12% in December 2024. The company has struggled to control its operating expenses relative to its revenue over the period.
Similarly, the pretax margin and net profit margin of the company have been consistently negative, showing a gradual improvement from severe losses in 2020 to relatively smaller losses in 2024. The pretax and net profit margins indicate the company's ability to generate profits after accounting for all expenses, interest, and taxes.
Overall, the profitability ratios of Myriad Genetics Inc demonstrate a challenging financial performance characterized by declining gross profit margins and persistent losses in operating, pretax, and net profit margins over the years covered in the data provided.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -9.90% | -10.71% | -14.37% | -20.99% | -22.45% | -23.67% | -21.64% | -13.77% | -10.32% | -9.97% | -12.87% | -12.64% | -14.42% | -14.64% | -11.42% | -15.17% | -20.43% | -17.33% | -16.50% | -11.68% |
| Return on assets (ROA) | -12.39% | -10.73% | -14.30% | -21.13% | -22.97% | -23.88% | -20.91% | -12.50% | -9.34% | -6.38% | -1.45% | -0.65% | -2.06% | -4.78% | -7.62% | -11.54% | -16.21% | -13.44% | -14.20% | -10.25% |
| Return on total capital | -11.34% | -15.16% | -20.70% | -30.61% | -33.12% | -40.09% | -35.20% | -19.28% | -13.96% | -13.17% | -3.63% | -1.71% | -4.86% | -7.26% | -17.01% | -23.91% | -22.43% | -15.41% | -12.73% | -8.76% |
| Return on equity (ROE) | -18.16% | -15.85% | -20.96% | -30.87% | -33.62% | -40.15% | -33.76% | -17.50% | -12.64% | -8.43% | -1.86% | -0.86% | -2.81% | -6.59% | -11.48% | -17.63% | -26.14% | -21.35% | -21.73% | -15.33% |
The profitability ratios of Myriad Genetics Inc indicate a declining trend over the reporting periods.
- Operating return on assets (Operating ROA) has decreased from -11.68% as of March 31, 2020, to -9.90% as of December 31, 2024, with fluctuations along the way.
- Return on assets (ROA) also shows a downward trend, falling from -10.25% on March 31, 2020, to -12.39% on December 31, 2024, with occasional drops and recoveries in between.
- Return on total capital similarly declined over the periods, from -8.76% on March 31, 2020, to -11.34% on December 31, 2024, experiencing fluctuations and periods of sharper declines.
- Return on equity (ROE) also decreased steadily from -15.33% on March 31, 2020, to -18.16% on December 31, 2024, with fluctuations and larger declines seen in some periods.
Overall, Myriad Genetics Inc's profitability ratios suggest a challenging financial performance with decreasing returns on assets, capital, and equity over the reporting periods, which may warrant a closer examination of the company's operational efficiency and financial management strategies.